All In Biotech

Drug Trial Radar · NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

A Randomized Phase II Study of Venetoclax and HMA-Based Therapies for the Treatment of Older and Unfit Adults With Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML): A MyeloMATCH Substudy

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

147

Planned (sponsor's estimate)

Start

Sep 27, 2024

Primary completion

May 15, 2029

Study completion May 15, 2029

Sponsor

Sponsor type
NIH
First posted
Mar 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II MyeloMATCH treatment trial compares the usual treatment of azacitidine and venetoclax to the combination treatment of azacitidine, venetoclax and gilteritinib in treating older and unfit patients with acute myeloid leukemia and FLT3 mutations. Azacitidine is a drug that is absorbed into DNA and leads to the activation of cancer suppressor genes, which are genes that help control cell growth. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Gilteritinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply. This study may help doctors find out if these different approaches are better than the usual approaches. To decide if they are better, the study doctors are looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to the usual approach.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • AzacitidineDrug

    Given IV or SC

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Bone Marrow AspirationProcedure

    Undergo bone marrow biopsy and aspiration

  • Bone Marrow BiopsyProcedure

    Undergo bone marrow biopsy and aspiration

  • GilteritinibDrug

    Given PO

  • VenetoclaxDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of measured residual disease (MRD) negative complete remission (CR)Time frame: Up to 4 cycles of treatment (1 cycle = 28 days)

Locations

229 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama · Recruiting

  • Banner University Medical Center - Tucson

    Tucson, Arizona · Recruiting

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona · Recruiting

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas · Recruiting

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California · Active not recruiting

  • Kaiser Permanente Dublin

    Dublin, California · Recruiting

  • Kaiser Permanente-Fremont

    Fremont, California · Recruiting

  • Kaiser Permanente Fresno Orchard Plaza

    Fresno, California · Recruiting

  • Kaiser Permanente-Fresno

    Fresno, California · Suspended

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Kaiser Permanente- Modesto MOB II

    Modesto, California · Recruiting

  • Kaiser Permanente-Modesto

    Modesto, California · Suspended

  • Kaiser Permanente-Oakland

    Oakland, California · Recruiting

  • Kaiser Permanente-Roseville

    Roseville, California · Recruiting

  • Kaiser Permanente Downtown Commons

    Sacramento, California · Recruiting

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • Kaiser Permanente-South Sacramento

    Sacramento, California · Recruiting

  • Kaiser Permanente-San Francisco

    San Francisco, California · Recruiting

  • UCSF Medical Center-Parnassus

    San Francisco, California · Recruiting

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California · Recruiting

  • Kaiser Permanente San Leandro

    San Leandro, California · Recruiting

  • Mills Health Center

    San Mateo, California · Active not recruiting

  • Kaiser San Rafael-Gallinas

    San Rafael, California · Recruiting

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California · Recruiting

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California · Recruiting

  • Kaiser Permanente-South San Francisco

    South San Francisco, California · Recruiting

  • Kaiser Permanente-Vallejo

    Vallejo, California · Recruiting

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • Veterans Affairs Connecticut Healthcare System-West Haven Campus

    West Haven, Connecticut · Recruiting

  • UF Health Cancer Institute - Gainesville

    Gainesville, Florida · Recruiting

  • Miami Cancer Institute

    Miami, Florida · Recruiting

  • Phoebe Putney Memorial Hospital

    Albany, Georgia · Recruiting

  • Augusta University Medical Center

    Augusta, Georgia · Suspended

  • Hawaii Cancer Care - Westridge

    ‘Aiea, Hawaii · Recruiting

  • Pali Momi Medical Center

    ‘Aiea, Hawaii · Recruiting

  • Hawaii Cancer Care Inc - Waterfront Plaza

    Honolulu, Hawaii · Recruiting

  • Straub Clinic and Hospital

    Honolulu, Hawaii · Recruiting

  • Kaiser Permanente Moanalua Medical Center

    Honolulu, Hawaii · Recruiting

  • Saint Alphonsus Cancer Care Center-Boise

    Boise, Idaho · Recruiting

Showing 40 of 229 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.